BIO vs. LLY: Bio-Rad Laboratories vs. Eli Lilly Stock Comparison

November 11, 2026

How do Bio-Rad Laboratories (BIO) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while LLY is classified in Pharmaceuticals.

Company profile comparison for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Profile Item	BIO	LLY
Name	Bio-Rad Laboratories Inc.	Eli Lilly and Company
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	10.26 billion USD	1,206.07 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	February 27, 1980	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIO

LLY

GSPC

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
Total Return (1Y)	28.31%	52.36%
Total Return (3Y, Annualized)	8.52%	34.18%
Total Return (5Y, Annualized)	-11.74%	41.08%

Risk Profile

Drawdown History

BIO

LLY

GSPC

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
Volatility (1Y, Annualized)	36.50%	35.34%
Beta (5Y)	1.03	0.40
Max Drawdown (5Y)	-72.24%	-34.48%
Avg. Volume (3M)	250.78K	2.52M

Risk-Adjusted Performance

Risk-Return Positioning

BIO and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
Sharpe Ratio (1Y)	0.66	1.36
Sortino Ratio (1Y)	0.98	2.29

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO) at 14.27% and Eli Lilly (LLY) at 86.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max: 109.18%
BIO: 14.27%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO) at 39.45% and Eli Lilly (LLY) at 31.90% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO: 39.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Eli Lilly (LLY) at 53.66% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.82%

Max: 83.12%
Q3: 14.77%
BIO: 11.82%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
ROE (TTM)	14.27%	86.02%
ROA (TTM)	1.50%	21.06%
Net Margin (TTM)	39.45%	31.90%
Operating Margin (TTM)	11.82%	53.66%
Gross Margin (TTM)	52.19%	83.63%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Eli Lilly (LLY) reports EPS growth of 95.99%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
Revenue Growth (YoY)	0.65%	44.70%
Revenue Growth (3Y CAGR)	-2.68%	31.69%
EPS Growth (YoY)	--	95.99%
EPS Growth (3Y CAGR)	--	51.71%

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max: 25.13
Q3: 12.13
Median: 5.52
BIO: 3.18
Q1: 2.47
Min: 0.10

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max: 1.42
Q3: 0.65
BIO: 0.18
Median: 0.15
Q1: 0.02
Min: 0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
Current Ratio (MRQ)	3.18	1.39
Debt / Equity (MRQ)	0.18	1.23
Net Debt / EBITDA	-0.73	0.96

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
Dividend Yield (TTM)	0.00%	0.49%
Dividend Payout Ratio (TTM)	0.00%	21.71%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.14

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
BIO: 10.14
Min: 0.07

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.96

Max: 58.18
Q3: 25.77
Median: 7.30
BIO: 3.96
Q1: 3.01
Min: 0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile relative to book while Eli Lilly (LLY) at 29.96 prices above its industry range — a wide valuation gap against assets.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BIO: 1.35
Min: -5.59

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Bio-Rad Laboratories (BIO) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO) and Eli Lilly (LLY)
Metric	BIO	LLY
P/E Ratio (TTM)	10.14	43.95
P/S Ratio (TTM)	3.96	13.95
P/B Ratio (MRQ)	1.35	29.96
Free Cash Flow Yield (TTM)	2.65%	0.77%